Comparison of gemcitabine-based chemotherapies for advanced biliary tract cancers by renal function: an exploratory analysis of JCOG1113
Abstract JCOG1113 is a randomized phase III trial in patients with advanced biliary tract cancers (BTCs) (UMIN000001685), and gemcitabine plus S-1 (GS) was not inferior to gemcitabine plus cisplatin (GC). However, poor renal function often results in high toxicity of S-1. Therefore, we examined whet...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Nature Portfolio
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/fb2d299674634abea61faf256923e408 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:fb2d299674634abea61faf256923e408 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:fb2d299674634abea61faf256923e4082021-12-02T17:41:30ZComparison of gemcitabine-based chemotherapies for advanced biliary tract cancers by renal function: an exploratory analysis of JCOG111310.1038/s41598-021-92166-32045-2322https://doaj.org/article/fb2d299674634abea61faf256923e4082021-06-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-92166-3https://doaj.org/toc/2045-2322Abstract JCOG1113 is a randomized phase III trial in patients with advanced biliary tract cancers (BTCs) (UMIN000001685), and gemcitabine plus S-1 (GS) was not inferior to gemcitabine plus cisplatin (GC). However, poor renal function often results in high toxicity of S-1. Therefore, we examined whether GS can be recommended for patients with low creatinine clearance (CCr). Renal function was classified by CCr as calculated by the Cockcroft-Gault formula: high CCr (CCr ≥ 80 ml/min) and low CCr (80 > CCr ≥ 50 ml/min). Of 354 patients, 87 patients on GC and 91 on GS were included in the low CCr group, while there were 88 patients on GC and 88 patients on GS in the high CCr group. The HR of overall survival for GS compared with GC was 0.687 (95% CI 0.504–0.937) in the low CCr group. Although the total number of incidences of all Grade 3–4 non-haematological adverse reactions was higher (36.0% vs. 11.8%, p = 0.0002), the number of patients who discontinued treatment was not different (14.1% vs. 16.9%, p = 0.679) for GS compared with GC in the low CCr group. This study suggests that GS should be selected for the treatment of advanced BTC patients with reduced renal function.Makoto UenoChigusa MorizaneTakuji OkusakaJunki MizusawaTomoko KataokaMasafumi IkedaMasato OzakaNaohiro OkanoKazuya SugimoriAkiko TodakaSatoshi ShimizuNobumasa MizunoTomohisa YamamotoKeiji SanoKazutoshi TobimatsuAkio KatanumaAtsushi MiyamotoHironori YamaguchiTomohiro NishinaHirofumi ShirakawaYasushi KojimaTakamasa OonoYasuyuki KawamotoMasayuki FurukawaTomohisa IwaiKentaro SudoHiroyuki MiyakawaTatsuya YamashitaIchirou YasudaHidenori TakahashiNaoya KatoKazuhiko ShiojiKyoko ShimizuToshio NakagohriKen KamataHiroshi IshiiJunji Furusethe members of the Hepatobiliary and Pancreatic Oncology Group of the Japan Clinical Oncology Group (JCOG-HBPOG).Nature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-9 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Makoto Ueno Chigusa Morizane Takuji Okusaka Junki Mizusawa Tomoko Kataoka Masafumi Ikeda Masato Ozaka Naohiro Okano Kazuya Sugimori Akiko Todaka Satoshi Shimizu Nobumasa Mizuno Tomohisa Yamamoto Keiji Sano Kazutoshi Tobimatsu Akio Katanuma Atsushi Miyamoto Hironori Yamaguchi Tomohiro Nishina Hirofumi Shirakawa Yasushi Kojima Takamasa Oono Yasuyuki Kawamoto Masayuki Furukawa Tomohisa Iwai Kentaro Sudo Hiroyuki Miyakawa Tatsuya Yamashita Ichirou Yasuda Hidenori Takahashi Naoya Kato Kazuhiko Shioji Kyoko Shimizu Toshio Nakagohri Ken Kamata Hiroshi Ishii Junji Furuse the members of the Hepatobiliary and Pancreatic Oncology Group of the Japan Clinical Oncology Group (JCOG-HBPOG). Comparison of gemcitabine-based chemotherapies for advanced biliary tract cancers by renal function: an exploratory analysis of JCOG1113 |
| description |
Abstract JCOG1113 is a randomized phase III trial in patients with advanced biliary tract cancers (BTCs) (UMIN000001685), and gemcitabine plus S-1 (GS) was not inferior to gemcitabine plus cisplatin (GC). However, poor renal function often results in high toxicity of S-1. Therefore, we examined whether GS can be recommended for patients with low creatinine clearance (CCr). Renal function was classified by CCr as calculated by the Cockcroft-Gault formula: high CCr (CCr ≥ 80 ml/min) and low CCr (80 > CCr ≥ 50 ml/min). Of 354 patients, 87 patients on GC and 91 on GS were included in the low CCr group, while there were 88 patients on GC and 88 patients on GS in the high CCr group. The HR of overall survival for GS compared with GC was 0.687 (95% CI 0.504–0.937) in the low CCr group. Although the total number of incidences of all Grade 3–4 non-haematological adverse reactions was higher (36.0% vs. 11.8%, p = 0.0002), the number of patients who discontinued treatment was not different (14.1% vs. 16.9%, p = 0.679) for GS compared with GC in the low CCr group. This study suggests that GS should be selected for the treatment of advanced BTC patients with reduced renal function. |
| format |
article |
| author |
Makoto Ueno Chigusa Morizane Takuji Okusaka Junki Mizusawa Tomoko Kataoka Masafumi Ikeda Masato Ozaka Naohiro Okano Kazuya Sugimori Akiko Todaka Satoshi Shimizu Nobumasa Mizuno Tomohisa Yamamoto Keiji Sano Kazutoshi Tobimatsu Akio Katanuma Atsushi Miyamoto Hironori Yamaguchi Tomohiro Nishina Hirofumi Shirakawa Yasushi Kojima Takamasa Oono Yasuyuki Kawamoto Masayuki Furukawa Tomohisa Iwai Kentaro Sudo Hiroyuki Miyakawa Tatsuya Yamashita Ichirou Yasuda Hidenori Takahashi Naoya Kato Kazuhiko Shioji Kyoko Shimizu Toshio Nakagohri Ken Kamata Hiroshi Ishii Junji Furuse the members of the Hepatobiliary and Pancreatic Oncology Group of the Japan Clinical Oncology Group (JCOG-HBPOG). |
| author_facet |
Makoto Ueno Chigusa Morizane Takuji Okusaka Junki Mizusawa Tomoko Kataoka Masafumi Ikeda Masato Ozaka Naohiro Okano Kazuya Sugimori Akiko Todaka Satoshi Shimizu Nobumasa Mizuno Tomohisa Yamamoto Keiji Sano Kazutoshi Tobimatsu Akio Katanuma Atsushi Miyamoto Hironori Yamaguchi Tomohiro Nishina Hirofumi Shirakawa Yasushi Kojima Takamasa Oono Yasuyuki Kawamoto Masayuki Furukawa Tomohisa Iwai Kentaro Sudo Hiroyuki Miyakawa Tatsuya Yamashita Ichirou Yasuda Hidenori Takahashi Naoya Kato Kazuhiko Shioji Kyoko Shimizu Toshio Nakagohri Ken Kamata Hiroshi Ishii Junji Furuse the members of the Hepatobiliary and Pancreatic Oncology Group of the Japan Clinical Oncology Group (JCOG-HBPOG). |
| author_sort |
Makoto Ueno |
| title |
Comparison of gemcitabine-based chemotherapies for advanced biliary tract cancers by renal function: an exploratory analysis of JCOG1113 |
| title_short |
Comparison of gemcitabine-based chemotherapies for advanced biliary tract cancers by renal function: an exploratory analysis of JCOG1113 |
| title_full |
Comparison of gemcitabine-based chemotherapies for advanced biliary tract cancers by renal function: an exploratory analysis of JCOG1113 |
| title_fullStr |
Comparison of gemcitabine-based chemotherapies for advanced biliary tract cancers by renal function: an exploratory analysis of JCOG1113 |
| title_full_unstemmed |
Comparison of gemcitabine-based chemotherapies for advanced biliary tract cancers by renal function: an exploratory analysis of JCOG1113 |
| title_sort |
comparison of gemcitabine-based chemotherapies for advanced biliary tract cancers by renal function: an exploratory analysis of jcog1113 |
| publisher |
Nature Portfolio |
| publishDate |
2021 |
| url |
https://doaj.org/article/fb2d299674634abea61faf256923e408 |
| work_keys_str_mv |
AT makotoueno comparisonofgemcitabinebasedchemotherapiesforadvancedbiliarytractcancersbyrenalfunctionanexploratoryanalysisofjcog1113 AT chigusamorizane comparisonofgemcitabinebasedchemotherapiesforadvancedbiliarytractcancersbyrenalfunctionanexploratoryanalysisofjcog1113 AT takujiokusaka comparisonofgemcitabinebasedchemotherapiesforadvancedbiliarytractcancersbyrenalfunctionanexploratoryanalysisofjcog1113 AT junkimizusawa comparisonofgemcitabinebasedchemotherapiesforadvancedbiliarytractcancersbyrenalfunctionanexploratoryanalysisofjcog1113 AT tomokokataoka comparisonofgemcitabinebasedchemotherapiesforadvancedbiliarytractcancersbyrenalfunctionanexploratoryanalysisofjcog1113 AT masafumiikeda comparisonofgemcitabinebasedchemotherapiesforadvancedbiliarytractcancersbyrenalfunctionanexploratoryanalysisofjcog1113 AT masatoozaka comparisonofgemcitabinebasedchemotherapiesforadvancedbiliarytractcancersbyrenalfunctionanexploratoryanalysisofjcog1113 AT naohirookano comparisonofgemcitabinebasedchemotherapiesforadvancedbiliarytractcancersbyrenalfunctionanexploratoryanalysisofjcog1113 AT kazuyasugimori comparisonofgemcitabinebasedchemotherapiesforadvancedbiliarytractcancersbyrenalfunctionanexploratoryanalysisofjcog1113 AT akikotodaka comparisonofgemcitabinebasedchemotherapiesforadvancedbiliarytractcancersbyrenalfunctionanexploratoryanalysisofjcog1113 AT satoshishimizu comparisonofgemcitabinebasedchemotherapiesforadvancedbiliarytractcancersbyrenalfunctionanexploratoryanalysisofjcog1113 AT nobumasamizuno comparisonofgemcitabinebasedchemotherapiesforadvancedbiliarytractcancersbyrenalfunctionanexploratoryanalysisofjcog1113 AT tomohisayamamoto comparisonofgemcitabinebasedchemotherapiesforadvancedbiliarytractcancersbyrenalfunctionanexploratoryanalysisofjcog1113 AT keijisano comparisonofgemcitabinebasedchemotherapiesforadvancedbiliarytractcancersbyrenalfunctionanexploratoryanalysisofjcog1113 AT kazutoshitobimatsu comparisonofgemcitabinebasedchemotherapiesforadvancedbiliarytractcancersbyrenalfunctionanexploratoryanalysisofjcog1113 AT akiokatanuma comparisonofgemcitabinebasedchemotherapiesforadvancedbiliarytractcancersbyrenalfunctionanexploratoryanalysisofjcog1113 AT atsushimiyamoto comparisonofgemcitabinebasedchemotherapiesforadvancedbiliarytractcancersbyrenalfunctionanexploratoryanalysisofjcog1113 AT hironoriyamaguchi comparisonofgemcitabinebasedchemotherapiesforadvancedbiliarytractcancersbyrenalfunctionanexploratoryanalysisofjcog1113 AT tomohironishina comparisonofgemcitabinebasedchemotherapiesforadvancedbiliarytractcancersbyrenalfunctionanexploratoryanalysisofjcog1113 AT hirofumishirakawa comparisonofgemcitabinebasedchemotherapiesforadvancedbiliarytractcancersbyrenalfunctionanexploratoryanalysisofjcog1113 AT yasushikojima comparisonofgemcitabinebasedchemotherapiesforadvancedbiliarytractcancersbyrenalfunctionanexploratoryanalysisofjcog1113 AT takamasaoono comparisonofgemcitabinebasedchemotherapiesforadvancedbiliarytractcancersbyrenalfunctionanexploratoryanalysisofjcog1113 AT yasuyukikawamoto comparisonofgemcitabinebasedchemotherapiesforadvancedbiliarytractcancersbyrenalfunctionanexploratoryanalysisofjcog1113 AT masayukifurukawa comparisonofgemcitabinebasedchemotherapiesforadvancedbiliarytractcancersbyrenalfunctionanexploratoryanalysisofjcog1113 AT tomohisaiwai comparisonofgemcitabinebasedchemotherapiesforadvancedbiliarytractcancersbyrenalfunctionanexploratoryanalysisofjcog1113 AT kentarosudo comparisonofgemcitabinebasedchemotherapiesforadvancedbiliarytractcancersbyrenalfunctionanexploratoryanalysisofjcog1113 AT hiroyukimiyakawa comparisonofgemcitabinebasedchemotherapiesforadvancedbiliarytractcancersbyrenalfunctionanexploratoryanalysisofjcog1113 AT tatsuyayamashita comparisonofgemcitabinebasedchemotherapiesforadvancedbiliarytractcancersbyrenalfunctionanexploratoryanalysisofjcog1113 AT ichirouyasuda comparisonofgemcitabinebasedchemotherapiesforadvancedbiliarytractcancersbyrenalfunctionanexploratoryanalysisofjcog1113 AT hidenoritakahashi comparisonofgemcitabinebasedchemotherapiesforadvancedbiliarytractcancersbyrenalfunctionanexploratoryanalysisofjcog1113 AT naoyakato comparisonofgemcitabinebasedchemotherapiesforadvancedbiliarytractcancersbyrenalfunctionanexploratoryanalysisofjcog1113 AT kazuhikoshioji comparisonofgemcitabinebasedchemotherapiesforadvancedbiliarytractcancersbyrenalfunctionanexploratoryanalysisofjcog1113 AT kyokoshimizu comparisonofgemcitabinebasedchemotherapiesforadvancedbiliarytractcancersbyrenalfunctionanexploratoryanalysisofjcog1113 AT toshionakagohri comparisonofgemcitabinebasedchemotherapiesforadvancedbiliarytractcancersbyrenalfunctionanexploratoryanalysisofjcog1113 AT kenkamata comparisonofgemcitabinebasedchemotherapiesforadvancedbiliarytractcancersbyrenalfunctionanexploratoryanalysisofjcog1113 AT hiroshiishii comparisonofgemcitabinebasedchemotherapiesforadvancedbiliarytractcancersbyrenalfunctionanexploratoryanalysisofjcog1113 AT junjifuruse comparisonofgemcitabinebasedchemotherapiesforadvancedbiliarytractcancersbyrenalfunctionanexploratoryanalysisofjcog1113 AT themembersofthehepatobiliaryandpancreaticoncologygroupofthejapanclinicaloncologygroupjcoghbpog comparisonofgemcitabinebasedchemotherapiesforadvancedbiliarytractcancersbyrenalfunctionanexploratoryanalysisofjcog1113 |
| _version_ |
1718379682726936576 |